ALZFORUM.ORG: Last year, people with dementia were most vulnerable, and this constrained research. Investigators adjusted and managed to make strides in important areas, from plasma tests for Aβ and tau to therapeutics. 2020 saw the first — if embattled — FDA filing for a new AD drug since 2003. If approved, it would be the first biologic treatment for this disease.
Read more »